

**EFFICIENCY OF DISPERGATED FORM
AMOXICILLIN/CLAVULANATE IN TREATMENT
OF PATIENTS WITH NON SEVERE
COMMUNITY-ACQUIRED PNEUMONIA**

O.Ya. Dziublyk, G.B. Kapitan, O.O. Mukhin, R.E. Sukhin

Resume. Studies have shown that oral soluble form of amoxicillin/clavulanate — AMOKSIKLAV QUICK-TAB (Sandoz d.d., Slovenia) at a dose of 875/125 mg twice a day contributes to the high efficiency of treatment non severe community acquired pneumonia patients.

Keywords: *community acquired pneumonia, antibacterial therapy, amoxicillin/clavulanate.*